AiCure

Funxional Therapeutics

Minerva Neurosciences expands executive team

Thursday, March 6, 2014 10:30 AM

Minerva Neurosciences, a developer of new therapies to treat neuropsychiatric diseases and disorders, has launched the new company web site (www.minervaneurosciences.com) following the successful transfer of the Minerva Neurosciences corporate headquarters from New Jersey to Cambridge, Mass. The establishment of a new corporate headquarters follows the recent appointment of Rogerio Vivaldi, M.D., MBA, as the new president and CEO, and Marc Beer as the new chairman of the board of directors of Minerva Neurosciences. The company was founded in 2013 by the merger of Cyrenaic Pharmaceuticals and Sonkei Pharmaceuticals.

More... »


Boehringer Ingelheim acquires Funxional's FX125L and somatotaxin portfolio

Monday, July 23, 2012 03:49 PM

Boehringer Ingelheim has agreed to acquire global rights to Funxional Therapeutics’ FX125L compound and somatotaxin program.

More... »


CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs